

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07D 295/185, 217/06, 311/90, C07C 271/20, 237/22, 235/74, A61K 31/495, 31/47, 31/35, 31/22, 31/16</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/10231</b> <b>(43) International Publication Date:</b> 20 March 1997 (20.03.97)
<b>(21) International Application Number:</b> PCT/US96/14719 <b>(22) International Filing Date:</b> 13 September 1996 (13.09.96)  <b>(30) Priority Data:</b> 60/003,678 14 September 1995 (14.09.95) US 08/646,071 7 May 1996 (07.05.96) US 08/646,513 7 May 1996 (07.05.96) US  <b>(71) Applicant:</b> CEPHALON, INC. [US/US]; 145 Brandywine Parkway, West Chester, PA 19380 (US). <b>(72) Inventor:</b> CHATTERJEE, Sankar, 228 Henley Road, Wynnewood, PA 19096 (US). <b>(74) Agents:</b> MILLER, Suzanne, E. et al.; Woodcock Washburn Kurtz Mackiewicz & Norris, 46th floor, One Liberty Place, Philadelphia, PA 19103 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> KETOMETHYLENE GROUP-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS  <b>(57) Abstract</b>  The present invention is directed to novel ketomethylene group-containing inhibitors of cysteine or serine proteases. Methods for the use of the protease inhibitors are also described.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## Ketomethylene Group-Containing Cysteine and Serine Protease Inhibitors

### Cross Reference To Related Applications

5           This application claims benefit of U.S. Provisional Application Serial No. 60/003,678, filed September 14, 1995, U.S. Application Serial No. 08/646,071, filed May 7, 1996, and U.S. Application Serial No. 08/646,513, filed May 7, 1996, the disclosures of which are  
10 hereby incorporated by reference in their entirety.

### Field of the Invention

Novel ketomethylene group-containing inhibitors of cysteine or serine proteases, methods for making these novel compounds, and methods for using the same are disclosed.

### 15           Background of the Invention

Numerous cysteine and serine proteases have been identified in human tissues. A "protease" is an enzyme which degrades proteins into smaller components (peptides). The terms "cysteine protease" and "serine protease" refer to  
20 proteases which are distinguished by the presence therein of a cysteine or serine residue which plays a critical role in the catalytic process. Mammalian systems, including humans, normally degrade and process proteins via a variety of

- 2 -

enzymes including cysteine and serine proteases. However, when present at elevated levels or when abnormally activated, cysteine and serine proteases may be involved in pathophysiological processes.

5           For example, calcium-activated neutral proteases ("calpains") comprise a family of intracellular cysteine proteases which are ubiquitously expressed in mammalian tissues. Two major calpains have been identified; calpain I and calpain II. While calpain II is the predominant form in  
10 many tissues, calpain I is thought to be the predominant form in pathological conditions of nerve tissues. The calpain family of cysteine proteases has been implicated in many diseases and disorders, including neurodegeneration, stroke, Alzheimer's, amyotrophy, motor neuron damage, acute  
15 central nervous system injury, muscular dystrophy, bone resorption, platelet aggregation, cataracts and inflammation. Calpain I has been implicated in excitatory amino-acid induced neurotoxicity disorders including ischemia, hypoglycemia, Huntington's Disease, and epilepsy.

20           The lysosomal cysteine protease cathepsin B has been implicated in the following disorders: arthritis, inflammation, myocardial infarction, tumor metastasis, and muscular dystrophy. Other lysosomal cysteine proteases include cathepsins C, H, L and S. Interleukin-1 $\beta$  converting  
25 enzyme ("ICE") is a cysteine protease which catalyzes the formation of interleukin-1 $\beta$ . Interleukin-1 $\beta$  is an immunoregulatory protein implicated in the following disorders: inflammation, diabetes, septic shock, rheumatoid arthritis, and Alzheimer's disease. ICE has also been  
30 linked to apoptotic cell death of neurons, which is implicated in a variety of neurodegenerative disorders including Parkinson's disease, ischemia, and amyotrophic lateral sclerosis (ALS).

Cysteine proteases are also produced by various  
35 pathogens. The cysteine protease clostripain is produced by Clostridium histolyticum. Other proteases are produced by Trypanosoma cruzi, malaria parasites Plasmodium falciparum

- 3 -

and P.vinckei and Streptococcus. Hepatitis A viral protease HAV C3 is a cysteine protease essential for processing of picornavirus structural proteins and enzymes.

Exemplary serine proteases implicated in degenerative disorders include thrombin, human leukocyte elastase, pancreatic elastase, chymase and cathepsin G. Specifically, thrombin is produced in the blood coagulation cascade, cleaves fibrinogen to form fibrin and activates Factor VIII; thrombin is implicated in thrombophlebitis, thrombosis and asthma. Human leukocyte elastase is implicated in tissue degenerative disorders such as rheumatoid arthritis, osteoarthritis, atherosclerosis, bronchitis, cystic fibrosis, and emphysema. Pancreatic elastase is implicated in pancreatitis. Chymase, an enzyme important in angiotensin synthesis, is implicated in hypertension, myocardial infarction, and coronary heart disease. Cathepsin G is implicated in abnormal connective tissue degradation, particularly in the lung.


Given the link between cysteine and serine proteases and various debilitating disorders, compounds which inhibit these proteases would be useful and would provide an advance in both research and clinical medicine. The present invention is directed to these, as well as other, important ends.

25

#### Summary of the Invention

The present invention is directed to novel cysteine and serine protease inhibitors which contain a ketomethylene group adjacent to the P2 position. They are represented by the following Formula I:

30




I

- 4 -

wherein:


Q is aryl having from about 6 to about 14 carbons, heteroaryl having from about 6 to about 14 ring atoms, aralkyl having from about 7 to about 15 carbons, alkyl  
 5 having from 1 to about 10 carbons, said alkyl groups being optionally substituted with one or more J groups, heteroalkyl having from 2 to about 7 carbons, arylheteroalkyl wherein the aryl portion can be unfused or fused with the heteroalkyl ring, alkoxy having from 1 to  
 10 about 10 carbons, aralkyloxy having from about 7 to about 15 carbons, a carbohydrate moiety optionally containing one or more alkylated hydroxyl groups, xanthene-9-yl, CH(*i*-C<sub>4</sub>H<sub>9</sub>)NHCbz, CH<sub>2</sub>N(*i*-C<sub>4</sub>H<sub>9</sub>)Cbz, or Formula II or III:



II

III

15 Y has the formula:



wherein:

R<sup>1</sup> and R<sup>2</sup> are independently H, alkyl having from  
 20 one to about 14 carbons, cycloalkyl having from 3 to about 10 carbons, or a natural or unnatural side chain of an L-amino acid, said alkyl and cycloalkyl groups being optionally substituted with one or more J groups;

J is halogen, lower alkyl, aryl, heteroaryl, amino  
 25 optionally substituted with one to three aryl or lower alkyl groups, guanidino, alkoxycarbonyl, aralkoxycarbonyl, alkoxy, hydroxy, or carboxy; and

- 5 -

G is hydrogen,  $C(=O)NR^3R^4$ ,  $C(=O)OR^3$  or  $CH_2R^5$ ;

wherein:

$R^3$  and  $R^4$  are each independently hydrogen, alkyl having from 1 to about 10 carbons, said alkyl groups  
5 being optionally substituted with one or more J groups, aryl having from about 6 to about 14 carbons, and aralkyl having from about 7 to about 15 carbons; and

$R^5$  is halogen.

In some preferred embodiments of the compounds of  
10 Formula I wherein G is hydrogen, and Q is alkyl substituted with J, said J is an  $\alpha$ -amino group that is tertiary (that is, trisubstituted with other than hydrogen).

In other preferred embodiments of the compounds of Formula I wherein G is hydrogen, Q is  $-CH(R^6)-NH(R^7)$  where  $R^7$   
15 is a protecting group and  $R^6$  is H, alkyl having from one to about 14 carbons, cycloalkyl having from 3 to about 10 carbons, or a natural or unnatural side chain of an L-amino acid, said alkyl and cycloalkyl groups being optionally substituted with one or more J groups.

20 Preferred embodiments of the compounds of Formula I include those wherein  $R^2$  is isobutyl,  $R^1$  is isobutyl, benzyl, or ethyl, G is hydrogen,  $C(=O)NHC_2H_5$ , or  $CH_2F$ , and Q is as previously defined.


The compounds of the invention are useful for the  
25 inhibition of cysteine and serine proteases. Beneficially, the compounds find utility in a variety of settings. For example, in a research arena, the claimed compounds can be used, for example, as standards to screen for natural and synthetic cysteine protease and serine protease inhibitors  
30 which have the same or similar functional characteristics as the disclosed compounds. In a clinical arena, our compounds can be used to alleviate, mediate, reduce and/or prevent disorders which are associated with abnormal and/or aberrant activity of cysteine proteases and/or serine proteases.  
35 Accordingly, methods for using the subject compounds, such as methods for inhibiting serine proteases or cysteine proteases comprising contacting said proteases with an

- 6 -

inhibitory amount of a compound of the invention are disclosed. Methodologies for making our ketomethylene group-containing inhibitors are also disclosed. These and other features of the compounds of the subject invention are set forth in more detail below.

#### Detailed Description of the Preferred Embodiments

Novel cysteine and serine protease inhibitors have been discovered which are represented by the general Formula I:




10

I

wherein:

Q is aryl having from about 6 to about 14 carbons, heteroaryl having from about 6 to about 14 ring atoms, aralkyl having from about 7 to about 15 carbons, alkyl having from 1 to about 10 carbons, said alkyl groups being optionally substituted with one or more J groups, heteroalkyl having from 2 to about 7 carbons, arylheteroalkyl wherein the aryl portion can be unfused or fused with the heteroalkyl ring, alkoxy having from 1 to about 10 carbons, aralkyloxy having from about 7 to about 15 carbons, a carbohydrate moiety optionally containing one or more alkylated hydroxyl groups, xanthene-9-yl, CH(*i*-C<sub>4</sub>H<sub>9</sub>)NHCBz, CH<sub>2</sub>N(*i*-C<sub>4</sub>H<sub>9</sub>)Cbz, or Formula II or III:




II

III



- 7 -

Y has the formula



wherein:

- 5           R<sup>1</sup> and R<sup>2</sup> are independently H, alkyl having from one to about 14 carbons, cycloalkyl having from 3 to about 10 carbons, or a natural or unnatural side chain of an L-amino acid, said alkyl and cycloalkyl groups being optionally substituted with one or more J groups;
- 10           J is halogen, lower alkyl, aryl, heteroaryl, amino optionally substituted with one to three aryl or lower alkyl groups, guanidino, alkoxycarbonyl, aralkoxycarbonyl, alkoxy, hydroxy, or carboxy; and
- G is hydrogen, C(=O)NR<sup>3</sup>R<sup>4</sup>, C(=O)OR<sup>3</sup> or CH<sub>2</sub>R<sup>5</sup>;
- 15           wherein:
- R<sup>3</sup> and R<sup>4</sup> are each independently hydrogen, alkyl having from 1 to about 10 carbons, said alkyl groups being optionally substituted with one or more J groups, aryl having from about 6 to about 14 carbons, and aralkyl having
- 20           from about 7 to about 15 carbons; and
- R<sup>5</sup> is halogen.

In some preferred embodiments of the compounds of Formula I wherein G is hydrogen, and Q is alkyl substituted with J, said J is an α-amino group that is tertiary.


- 25           In other preferred embodiments of the compounds of Formula I wherein G is hydrogen, Q is -CH(R<sup>6</sup>)-NH(R<sup>7</sup>) where R<sup>7</sup> is a protecting group and R<sup>6</sup> is H, alkyl having from one to about 14 carbons, cycloalkyl having from 3 to about 10 carbons, or a natural or unnatural side chain of an L-amino
- 30           acid, said alkyl and cycloalkyl groups being optionally substituted with one or more J groups.

- In some preferred embodiments of the compounds of Formula I, R<sup>2</sup> is isobutyl. In other preferred embodiments of the compounds of Formula I, R<sup>1</sup> is isobutyl, benzyl, or ethyl.
- 35           In further preferred embodiments of the compounds of Formula

- 8 -

I, G is hydrogen,  $C(=O)NHC_2H_5$ , or  $CH_2F$ .

Preferably, Q is  $-(CH_2)_4-C_6H_5$ , diphenylmethyl, xanthen-9-yl or Q has the Formula II or III:



II

III

5 In further preferred embodiments Q is  $-CH(C_2H_5)(C_6H_5)$  or  $-CH(i-C_4H_9)NHCbz$ , with  $-(S)-CH(C_2H_5)(C_6H_5)$  and  $-(S)-CH(i-C_4H_9)NHCbz$  being particularly preferred.

In especially preferred embodiments  $R^2$  is isobutyl,  $R^1$  is isobutyl or benzyl, G is hydrogen,  $-CH_2F$  or  
 10  $-C(=O)NHC_2H_5$ , and Q is  $-(CH_2)_4-C_6H_5$ , diphenylmethyl, xanthen-9-yl,  $-(S)-CH(C_2H_5)(C_6H_5)$ ,  $-(S)-CH(i-C_4H_9)NHCbz$  or Q has the Formula II or III above.

As used herein, the term "alkyl" is meant to include straight-chain, branched and cyclic hydrocarbon  
 15 groups such as, for example, ethyl, isopropyl and cyclopropyl groups. Preferred alkyl groups have 1 to about 10 carbon atoms. "Cycloalkyl" groups are cyclic alkyl groups. "Aryl" groups are aromatic cyclic compounds including but not limited to phenyl, tolyl, naphthyl,  
 20 anthracyl, phenanthryl, pyrenyl, and xylyl. Preferred aryl groups include phenyl and naphthyl. The term "carbocyclic", as used herein, refers to cyclic groups in which the ring portion is composed solely of carbon atoms. The term "heterocyclic" refers to cyclic groups in which the ring  
 25 portion includes at least one heteroatom such as O, N or S. "Heteroalkyl" groups are heterocycles containing solely single bonds within their ring portions, i.e. saturated heteroatomic ring systems. The term "lower alkyl" refers to alkyl groups of 1-4 carbon atoms. The term "halogen" refers  
 30 to F, Cl, Br, and I atoms.




The term "aralkyl" denotes alkyl groups which bear aryl groups, for example, benzyl groups. The term "aralkyloxy" denotes an aralkyl group linked through an

- 9 -













oxygen atom. The term "heteroaryl" denotes aryl groups having one or more heteroatoms contained within an aromatic ring. "Heteroaralkyl" groups are aralkyl groups which have one or more heteroatoms in their aromatic ring portion. The  
 5 term "carbohydrate" includes monosaccharides, disaccharides, and polysaccharides, as well as their protected derivatives, such as, for example, mono- and diisopropylidene, and benzylidene derivatives.

As used herein, the term "amino acid" denotes a  
 10 molecule containing both an amino group and a carboxyl group. As used herein the term "L-amino acid" denotes an  $\alpha$ -amino acid having the L configuration around the  $\alpha$ - carbon, that is, a carboxylic acid of general formula  $\text{CH}(\text{COOH})(\text{NH}_2)$ -(sidechain), having the L-configuration.  
 15 Sidechains of L-amino acids include naturally occurring and non-naturally occurring moieties. Nonnaturally occurring amino acid sidechains are moieties that are used in place of naturally occurring amino acid sidechains in, for example, amino acid analogs. See, for example, Lehninger,  
 20 *Biochemistry*, Second Edition, Worth Publishers, Inc, 1975, pages 73-75. Representative  $\alpha$ -amino acid sidechains are shown below on Table 1.


Table 1

CH <sub>3</sub> -	HS-CH <sub>2</sub> -
25 HO-CH <sub>2</sub> -	HO <sub>2</sub> C-CH(NH <sub>2</sub> )-CH <sub>2</sub> -S-S-CH <sub>2</sub> -
C <sub>6</sub> H <sub>5</sub> -CH <sub>2</sub> -	CH <sub>3</sub> -CH <sub>2</sub> -
HO-C <sub>6</sub> H <sub>4</sub> -CH <sub>2</sub> -	CH <sub>3</sub> -S-CH <sub>2</sub> -CH <sub>2</sub> -
	CH <sub>3</sub> -CH <sub>2</sub> -S-CH <sub>2</sub> -CH <sub>2</sub> -
	HO-CH <sub>2</sub> -CH <sub>2</sub> -
	CH <sub>3</sub> -CH(OH)-
	HO <sub>2</sub> C-CH <sub>2</sub> -NHC(=O)-CH <sub>2</sub> -
	
	HO <sub>2</sub> C-CH <sub>2</sub> -CH <sub>2</sub> -
	NH <sub>2</sub> C(=O)-CH <sub>2</sub> -CH <sub>2</sub> -


- 10 -




Functional groups present on the compounds of Formula I may contain protecting groups. Protecting groups are known *per se* as chemical functional groups that can be selectively appended to and removed from functionalities, such as hydroxyl groups and carboxyl groups. These groups are present in a chemical compound to render such functionality inert to chemical reaction conditions to which the compound is exposed. Any of a variety of protecting groups may be employed with the present invention. One such protecting group is the benzyloxycarbonyl (Cbz; Z) group. Other protecting groups include the phthalimido arylcarbonyls, alkylcarbonyls, alkoxycarbonyls, aryloxycarbonyls, aralkyloxycarbonyls, alkyl- and aralkylsulfonyls, and arylsulfonyl groups such as those which have the following formulas:




MTR



MTS



PMC



TOS

- 11 -

Other preferred protecting groups according to the invention may be found in Greene, T.W. and Wuts, P.G.M., *"Protective Groups in Organic Synthesis"* 2d. Ed., Wiley & Sons, 1991.

Because the ketomethylene group-containing  
5 components of the invention inhibit cysteine proteases and serine proteases, they can be used in both research and therapeutic settings.

In a research environment, preferred compounds having defined attributes can be used to screen for natural  
10 and synthetic compounds which evidence similar characteristics in inhibiting protease activity. The compounds can also be used in the refinement of *in vitro* and *in vivo* models for determining the effects of inhibition of particular proteases on particular cell types or biological  
15 conditions. In a therapeutic setting, given the connection between cysteine proteases and certain defined disorders, and serine proteases and certain defined disorders, compounds of the invention can be utilized to alleviate, mediate, reduce and/or prevent disorders which are  
20 associated with abnormal and/or aberrant activity of cysteine proteases and/or serine proteases.

In preferred embodiments, compositions are provided for inhibiting a serine protease or a cysteine protease comprising a compound of the invention. In other  
25 preferred embodiments, methods are provided for inhibiting serine proteases or cysteine proteases comprising contacting a protease selected from the group consisting of serine proteases and cysteine proteases with an inhibitory amount of a compound of the invention.

30 The disclosed compounds of the invention are useful for the inhibition of cysteine proteases and serine proteases. As used herein, the terms "inhibit" and "inhibition" mean having an adverse effect on enzymatic activity. An inhibitory amount is an amount of a compound  
35 of the invention effective to inhibit a cysteine and/or serine protease.

Pharmaceutically acceptable salts of the cysteine

- 12 -

and serine protease inhibitors also fall within the scope of the compounds as disclosed herein. The term "pharmaceutically acceptable salts" as used herein means an inorganic acid addition salt such as hydrochloride, sulfate, and phosphate, or an organic acid addition salt such as acetate, maleate, fumarate, tartrate, and citrate. Examples of pharmaceutically acceptable metal salts are alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt, and zinc salt. Examples of pharmaceutically acceptable organic amine addition salts are salts with morpholine and piperidine. Examples of pharmaceutically acceptable amino acid addition salts are salts with lysine, glycine, and phenylalanine.

Compounds provided herein can be formulated into pharmaceutical compositions by admixture with pharmaceutically acceptable nontoxic excipients and carriers. As noted above, such compositions may be prepared for use in parenteral administration, particularly in the form of liquid solutions or suspensions; or oral administration, particularly in the form of tablets or capsules; or intranasally, particularly in the form of powders, nasal drops, or aerosols; or dermally, via, for example, transdermal patches; or prepared in other suitable fashions for these and other forms of administration as will be apparent to those skilled in the art.

The composition may conveniently be administered in unit dosage form and may be prepared by any of the methods well known in the pharmaceutical art, for example, as described in *Remington's Pharmaceutical Sciences* (Mack Pub. Co., Easton, PA, 1980). Formulations for parenteral administration may contain as common excipients sterile water or saline, polyalkylene glycols such as polyethylene glycol, oils and vegetable origin, hydrogenated naphthalenes and the like. In particular, biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be useful

- 13 -

excipients to control the release of the active compounds. Other potentially useful parenteral delivery systems for these active compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation administration contain as excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally. Formulations for parenteral administration may also include glycocholate for buccal administration, a salicylate for rectal administration, or citric acid for vaginal administration. Formulations for transdermal patches are preferably lipophilic emulsions.

The materials for this invention can be employed as the sole active agent in a pharmaceutical or can be used in combination with other active ingredients which could facilitate inhibition of cysteine and serine proteases in diseases or disorders.

The concentrations of the compounds described herein in a therapeutic composition will vary depending upon a number of factors, including the dosage of the drug to be administered, the chemical characteristics (e.g., hydrophobicity) of the compounds employed, and the route of administration. In general terms, the compounds of this invention may be provided in effective inhibitory amounts in an aqueous physiological buffer solution containing about 0.1 to 10% w/v compound for parenteral administration. Typical dose ranges are from about 1 $\mu$ g/kg to about 1 g/kg of body weight per day; a preferred dose range is from about 0.01 mg/kg to 100 mg/kg of body weight per day. Such formulations typically provide inhibitory amounts of the compound of the invention. The preferred dosage of drug to be administered is likely, however, to depend on such variables as the type or extent of progression of the disease or disorder, the overall health status of the

- 14 -

particular patient, the relative biological efficacy of the compound selected, and formulation of the compound excipient, and its route of administration.

As used herein, the term "contacting" means  
5 directly or indirectly causing at least two moieties to come into physical association with each other. Contacting thus includes physical acts such as placing the moieties together in a container, or administering moieties to a patient. Thus, for example administering a compound of the invention  
10 to a human patient evidencing a disease or disorder associated with abnormal and/or aberrant activity of such proteases falls within the scope of the definition of the term "contacting".

The invention is further illustrated by way of the  
15 following examples which are intended to elucidate the invention. These examples are not intended, nor are they to be construed, as limiting the scope of the disclosure.


#### Examples

Compounds of the invention were prepared by the  
20 following procedures.  $R_f$  values are reported using standard silica gel and analytical plates.

The synthesis of compounds of general Formula 1-8 are summarized in Scheme I below:



## SCHEME I



## Example 1

## Synthesis of Intermediates 2a-e: General Procedure

To a cooled (0°C) solution of acid 1a-e (0.04-0.05 mole) in anhydrous tetrahydrofuran (40-50mL) was added 1,1'-5 carbonyldiimidazole (1.05 eqv.). The mixture was stirred at

- 16 -

0°C for 0.5 hour and then at room temperature overnight. The next morning, this solution was added slowly, over 1 hour, to a cooled (-78°C) solution of tert-butyl lithioacetate (2.2 eqv. for 1a-d and 3.3 eqv. for 1e, generated *in situ* from tert-butyl acetate and lithium diisopropylamide) in tetrahydrofuran (40-50 mL) and hexane (35-40 mL). The mixture was stirred for an additional 0.5 hour and quenched with 1N HCl (2.2 eqv. for 1a-d and 3.3 eqv. for 1e), brought to 0°C and acidified with 1N HCl to pH 3-4. The resulting aqueous solution was extracted with ethyl acetate (2 x 100mL). The organic layer was washed with brine (1 x 40mL), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure.

Purification of the crude material by flash chromatography (silica gel, 5-6% ethyl acetate in hexane for 1a-d and 12% ethyl acetate in hexane for 1e) gave the desired product 2a-e in 60-70% yield. A general description of this procedure can be found in Harris, B. D. et al., *Tetrahedron Lett.* 28(25), 2837 (1987), and in Hamada, Y. et al., *J. Am. Chem. Soc.* 111, 669 (1989).

Compound 2a: Colorless oil;  $R_f$  (10% ethyl acetate in hexane): 0.37;  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.30-7.10 (m, 5H), 3.35 (s, 2H), 2.60 (m, 2H), 2.50 (m, 2H), 1.60 (m, 4H), 1.45 (s, 9H).

Compound 2b: Colorless oil;  $R_f$  (10% ethyl acetate in hexane): 0.49;  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.38-7.18 (m, 5H), 3.70 (t, 1H), 3.35 (d, 1H), 3.20 (d, 1H), 2.10 (m, 1H), 1.70 (m, 1H), 1.45 (s, 9H), 0.85 (t, 3H).

Compound 2c: Colorless oil;  $R_f$  (10% ethyl acetate in hexane): 0.47;  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.20 (m, 10H), 5.35 (s, 1H), 3.45 (s, 1H), 1.45 (s, 9H).

Compound 2d: White solid, mp 101-103 °C;  $R_f$  (10% ethyl acetate in hexane): 0.46;  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.40 - 7.00 (m, 8H), 5.00 (s, 1H), 3.20 (s, 2H), 1.40 (s, 9H).

- 17 -

Compound 2e: Colorless oil;  $R_f$  (20% ethyl acetate in hexane): 0.45;  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.20 (m, 5H), 5.30 (d, 1H), 5.10 (s, 2H), 4.50 (m, 1H), 3.50 (d, 1H), 3.40 (d, 1H), 1.80-1.60 (m, 2H), 1.55 (m, 1H), 1.50 (s, 9H), 1.00-0.80 (2 sets of doublet, 6H).

## Example 2

### Synthesis of Intermediates 4a-e: General Procedure

A solution of the keto-ester 2a-e (0.02-0.03 mole) in anhydrous tetrahydrofuran (20-25 mL) was slowly added, at room temperature, to a slurry of 60% sodium hydride in oil (1.05 eqv.) in anhydrous tetrahydrofuran (10-15 mL). After the evolution of hydrogen gas ceased, the solution was treated with 1.2-1.3 eqv. of triflate-ester 3 (generated from the corresponding (R)-hydroxyester and triflic anhydride in presence of 2,6-lutidine). The reaction mixture was stirred overnight, diluted with ether (100-150 mL), washed with water (30-40 mL), dried over magnesium sulfate and concentrated under reduced pressure to give the crude diester intermediate. This material was dissolved in trifluoroacetic acid (8-10 mL) and stirred at room temperature for 1-2 hours. Excess trifluoroacetic acid was removed and the residue was taken into benzene (30-40 mL) and heated at reflux for 1-2 hours. The solvent was removed under reduced pressure and the crude product was purified by flash chromatography (silica gel, 4-5% ethyl acetate in hexane for 2a-d and 12% ethyl acetate in hexane for 2e) to give the desired compound 4a-e in 35-45% yield over three steps. The method described above, was adapted from the procedure described in Hoffman, R. V. et al., *Tetrahedron Lett.* 34 (13), 2051 (1993), and *J. Org. Chem.* 60, 5107-5113 (1995).

4a: Colorless oil;  $R_f$  (10% ethyl acetate in hexane): 0.34;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.35-7.15 (m, 5H), 3.65 (s, 3H), 2.90-2.80 (m, 2H), 2.60 (m, 2H), 2.50-2.30 (m, 3H), 1.70-1.50 (m, 6H), 1.25 (m, 1H), 1.95 (d, 3H), 1.85 (d, 3H).

- 18 -

4b: Colorless oil;  $R_f$  (10% ethyl acetate in hexane): 0.48;  
 $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.18 (m, 5H), 3.60 (s, 3H),  
3.50 (t, 1H), 2.85 (m, 1H), 2.75 (m, 1H), 2.45 (dd, 1H),  
2.05 (m, 1H), 1.70 (m, 1H), 1.45 (m, 2H), 1.15 (m, 1H),  
5 0.90-0.70 (m, 9H).

4c: White solid, mp 64.5-65.5 °C;  $R_f$  (10% ethyl acetate in  
hexane): 0.41;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.15 (m, 10H),  
5.15 (s, 1H), 3.65 (s, 3H), 3.00-2.85 (m, 2H), 2.60 (q, 1H),  
1.50 (m, 2H), 1.20 (m, 1H), 0.90 (d, 3H), 0.80 (d, 3H).

10 4d: Colorless oil;  $R_f$  (10% ethyl acetate in hexane): 0.40;  
 $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.18 (m, 8H), 4.90 (s, 1H),  
3.55 (s, 3H), 2.80-2.60 (m, 2H), 2.30 (dd, 1H), 1.30 (m,  
2H), 1.00 (m, 1H), 0.80 (d, 3H), 0.70 (d, 3H).

4e: Colorless oil;  $R_f$  (20% ethyl acetate in hexane): 0.43;  
15  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.20 (m, 5H), 5.20 (d, 1H),  
5.10 (s, 2H), 4.40 (m, 1H), 3.65 (s, 3H), 3.10-2.90 (m, 2H),  
2.60 (m, 1H), 1.80-1.45 (m, 4H), 1.40-1.20 (m, 2H), 1.00-  
0.80 (m, 12H).

### Example 3

#### 20 Synthesis of Intermediates 5a-e: General Procedure

A mixture of the ester 4a-e (0.005-0.006 mole),  
lithium hydroxide-monohydrate (1.3-1.4 eqv.), methanol (25-  
30 mL) and water (8-10 mL) was gently heated at 70-75°C for  
1.5-2.0 hours. Methanol was removed under reduced pressure.  
25 The aqueous layer was washed with diethyl ether (20-25 mL),  
acidified at 0°C with 1N HCl and then extracted into diethyl  
ether (3 x 20 mL). The organic layer was washed with brine  
(1 x 10 mL) and dried over anhydrous sodium sulfate.  
Solvent evaporation at reduced pressure yielded the  
30 intermediates 5a-e in 85-90% yield which were used without  
further purification.

5a: Colorless oil;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.35 (m, 5H),  
3.00-2.70 (m, 2H), 2.60 (q, 2H), 2.50-2.30 (m, 3H), 1.70-

- 19 -

1.50 (m, 6H), 1.35-1.20 (m, 1H), 1.95 (d, 3H), 1.85 (d, 3H).

5b: White solid, mp 61-63 °C; <sup>1</sup>H-NMR (300MHz, CDCl<sub>3</sub>) δ 7.40-7.10 (m, 5H), 3.60 (m, 1H), 2.90 (m, 1H), 2.75 (m, 1H), 2.50 (m, 1H), 2.05 (m, 1H), 1.70 (m, 1H), 1.50 (m, 2H), 1.15 (m, 5 1H), 0.90-0.70 (m, 9H).

5c: White solid, mp 81.5-83.5 °C; <sup>1</sup>H-NMR (300MHz, CDCl<sub>3</sub>) δ 7.40-7.10 (m, 10H), 5.15 (s, 1H), 3.00-2.85 (m, 2H), 2.60-2.70 (m, 1H), 1.60-1.40 (m, 2H), 1.30-1.20 (m, 1H), 0.90 (d, 3H), 0.80 (d, 3H).

10 5d: White solid, mp 125-127 °C; <sup>1</sup>H-NMR (300MHz, CDCl<sub>3</sub>) δ 7.40-7.00 (m, 8H), 4.95 (s, 1H), 2.80-2.60 (m, 2H), 2.30 (dd, 1H), 1.35 (m, 2H), 1.00 (m, 1H), 0.80 (d, 3H), 0.70 (d, 3H).

5e: Colorless oil; <sup>1</sup>H-NMR (300MHz, CDCl<sub>3</sub>) δ 7.40-7.20 (m, 5H), 5.25 (d, 1H), 5.20-5.00 (m, 2H), 4.40-4.20 (2 sets of 15 multiplets, 84:16, 1H), 3.00-2.80 (m, 2H), 2.65-2.50 (m, 1H), 1.80-1.50 (m, 4H), 1.45-1.20 (m, 2H), 1.00-0.80 (m, 12H).

#### Example 4 Synthesis of Intermediates 6a-b

20 Compounds 6a-b were generated as a mixture of diastereomers following the procedure of Harbeson, S. L. et al. as described in *J. Med. Chem.* 37, 2918 (1994).

#### Example 5 Synthesis of Intermediates 7a-f: General Procedure

25 To a cooled (-20°C) solution of 5a-e (0.50-1.00 mmol) in anhydrous tetrahydrofuran (3-4 mL) was added N-methylmorpholine (3.3 eqv.) followed by isobutyl chloroformate (1.1 eqv.). The mixture was stirred for 15 minutes by which time the temperature changed to 0°C. A 30 solution of 6a-b (1 eqv.) in anhydrous N,N-dimethylformamide (3-4 mL) was added to the reaction mixture. The cooling bath was removed and the mixture was stirred for another 2

- 20 -

hours. The resulting mixture was then poured into water (5-8 mL) and extracted into ethyl acetate (3 x 15 mL). The organic layer was washed with 2% citric acid solution (2 x 5 mL), saturated sodium bicarbonate solution (2 x 5 mL), brine (1 x 5 mL) and dried over anhydrous sodium sulfate. Solvent evaporation under reduced pressure gave a crude material which was purified by flash chromatography (silica gel, 2-3% methanol-methylene chloride) to produce 7a-f as diastereomeric mixtures (at hydroxy center) in 25-30% yield.

10 7a: Diastereomers; white solid, mp 97-99 °C;  $R_f$  (5% methanol in methylene chloride): 0.47;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.30-7.10 (m, 5H), 6.95-6.80 (broad, 1H), 6.30 (d, 1H), 5.80-5.50 (broad, 1H), 4.15 (s, 1H), 3.90-3.80 (m, 1H), 3.40-3.10 (m, 2H), 2.90-2.70 (m 2H), 2.65-2.55 (broad, 2H), 2.45-2.35 (m, 15 3H), 2.00-1.70 (m 2H), 1.65-1.40 (m, 7H), 1.20-1.00 (t, 3H), 0.95-0.75 (m, 9H).

7b: Separated diastereomers:

The faster moving isomer was a white solid, mp 150-160 °C (softening to melt);  $R_f$  (5% methanol in methylene chloride): 0.37;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.10 (m, 5H), 7.00-6.80 (m, 1H), 6.80-6.70 (m, 1H), 4.30-3.60 (m, 3H), 3.60-3.50 (m, 1H), 3.40-3.20 (m, 3H), 2.80-2.60 (m, 2H), 2.60-2.40 (m, 1H), 2.10-1.90 (m, 2H), 1.80-1.60 (m, 2H), 1.50-1.30 (m, 2H), 1.25-1.10 (m, 3H), 1.00-0.70 (m, 12H);

25 The slower moving isomer was a white solid, mp 115-130 °C (softening to melt);  $R_f$  (5% methanol in methylene chloride): 0.35;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.10 (m, 5H), 7.00-6.80 (m, 1H), 6.80-6.70 (m, 1H), 4.30-3.60 (m, 3H), 3.60-3.50 (m, 1H), 3.40-3.20 (m, 3H), 2.80-2.60 (m, 2H), 30 2.60-2.40 (m, 1H), 2.10-1.90 (m, 2H), 1.80-1.60 (m, 2H), 1.50-1.30 (m, 2H), 1.25-1.10 (m, 3H), 1.00-0.70 (m, 12H).

7c: Separated diastereomers:

The faster moving isomer was a white solid, mp 134-154 °C (softening to melt);  $R_f$  (5% methanol in methylene

- 21 -

chloride): 0.44; <sup>1</sup>H-NMR (300MHz, CDCl<sub>3</sub>) δ 7.40-7.10 (m, 10H), 6.95-6.85 (broad, 1H), 6.20 (d, 1H), 5.75-5.55 (broad, 1H), 5.10 (s, 1H), 4.15 (s, 1H), 3.90-3.75 (m, 1H), 3.40-3.25 (m, 1H), 3.20-3.05 (m, 1H), 3.05-2.95 (dd, 1H), 2.85-2.70 (m, 1H), 2.65-2.50 (dd, 1H), 1.90-1.60 (m, 3H), 1.60-1.40 (m, 2H), 1.20-1.05 (t, 3H), 1.00-0.75 (m, 9H);

The slower moving isomer was a white solid, mp 124-144 °C (softening to melt); R<sub>f</sub> (5% methanol in methylene chloride): 0.38; <sup>1</sup>H-NMR (300MHz, CDCl<sub>3</sub>) δ 7.40-7.10 (m, 10H), 6.95-6.85 (broad, 1H), 6.20 (d, 1H), 5.75-5.55 (broad, 1H), 5.10 (s, 1H), 4.15 (s, 1H), 3.90-3.75 (m, 1H), 3.40-3.25 (m, 1H), 3.20-3.05 (m, 1H), 3.05-2.95 (dd, 1H), 2.85-2.70 (m, 1H), 2.65-2.50 (dd, 1H), 1.90-1.60 (m, 3H), 1.60-1.40 (m, 2H), 1.20-1.05 (t, 3H), 1.00-0.75 (m, 9H).

7d: Diastereomers: white solid, mp 185-195 °C (softening to melt); R<sub>f</sub> (5% methanol in methylene chloride): 0.46; <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) δ 7.40-7.00 (m, 8H), 6.90-6.80 and 6.70-6.60 (2 sets of m, 1:1, 1H), 6.25 and 6.00 (2 sets of d, 1H), 5.65-5.55 and 5.40-5.30 (2 sets of m, 1:1, 1H), 4.90 (s, 1H), 4.10 (d, 1H), 3.80-3.60 (m, 1H), 3.40-3.00 (m, 2H), 2.70-2.40 (m, 2H), 2.40-2.20 (dt, 1H), 1.80-1.40 (m, 3H), 1.40-1.20 (m, 2H), 1.15-1.00 (m, 3H), 1.00-0.80 (m, 3H), 0.80-0.60 (m, 6H).

7e: Diastereomers: white solid, mp 115-125 °C (softening to melt); R<sub>f</sub> (5% methanol in methylene chloride): 0.47; <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) δ 7.40-7.20 (m, 5H), 6.95-6.85 (broad, 1H), 6.30-6.20 (m, 1H), 5.30-5.10 (m, 2H), 5.05 (d, 2H), 4.40-4.20 (m, 1H), 4.00-3.80 (m, 1H), 3.35-3.10 (m, 2H), 3.00-2.70 (m, 2H), 2.55-2.40 (m, 1H), 2.00-1.20 (m, 9H), 1.15-1.05 (t, 3H), 1.00-0.70 (m, 15H).

7f: Diastereomers: white solid, mp 196-201 °C (softening to melt); R<sub>f</sub> (5% methanol in methylene chloride): 0.47; <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) δ 7.40-7.00 (m, 8H), 6.95-6.85 (broad, 1H), 6.05 (d, 1H), 5.35 (d, 1H), 4.90 (s, 1H), 4.05 (d, 1H),

- 22 -

4.00-3.90 (m, 1H), 3.40-3.20 (m, 1H), 3.20-3.10 (m, 1H),  
2.65-2.60 (dd, 1H), 2.60-2.45 (m, 1H), 2.30-2.20 (dd, 1H),  
1.90-1.70 (m, 2H), 1.70-1.50 (m, 1H), 1.45-1.20 (m, 3H),  
1.15 (t, 3H), 0.95 (d, 3H), 0.85 (d, 3H), 0.80 (d, 3H),  
5 0.70 (d, 3H).

**Example 6****Synthesis of Ketoamides 8a-f: General Procedure**

To a cooled (0°C) solution of 7a-f (0.05-0.10 mmol)  
in anhydrous methylene chloride (2-3 mL) was added Dess-  
10 Martin periodinate reagent (3.00-4.00 eqv.). The cooling  
bath was removed and the mixture was stirred for an  
additional 30-45 minutes. It was then diluted with  
methylene chloride (10-15 mL) and washed with 10% sodium  
thiosulfate solution (5 x 5 mL), saturated sodium  
15 bicarbonate solution (2 x 5 mL) and brine (1 x 5 mL).  
Drying over anhydrous sodium sulfate and solvent removal  
under reduced pressure gave a material which was washed with  
n-pentane (5-8 mL) and dried under vacuum to generate the  
desired target 8a-f in 50-60% yield. A general description  
20 of the procedure can be found in Patel, D.V. et al., *J. Med.*  
*Chem.* 36, 2431-2447 (1993).

8a: White solid, mp 123-124 °C;  $R_f$  (5% methanol in methylene  
chloride): 0.50;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.30-7.10 (m, 5H),  
6.95-6.80 (broad, 1H), 6.30 (d, 1H), 5.30-5.10 (m, 1H),  
25 3.40-3.30 (m, 2H), 2.90-2.70 (m 2H), 2.65-2.55 (broad, 2H),  
2.45-2.35 (m, 3H), 2.10-1.90 (m 1H), 1.75-1.40 (m, 8H),  
1.30-1.00 (m, 3H), 0.95-0.75 (m, 9H).

8b: White solid, mp 105-115 °C (softening to melt);  $R_f$  (5%  
methanol in methylene chloride): 0.53;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  
30  $\delta$  7.40-7.10 (m, 5H), 7.00-6.80 (broad, 1H), 6.35-6.20 (m,  
1H), 5.35-5.20 (m, 1H), 5.20-5.00 (m, 1H), 3.60-3.50 (m,  
1H), 3.40-3.20 (m, 3H), 2.90-2.70 (m, 2H), 2.40 (dt, 1H),  
2.10-1.90 (m, 2H), 1.80-1.60 (m, 2H), 1.50-1.30 (m, 1H),  
1.25-1.10 (m, 3H), 1.00-0.70 (m, 12H).



- 23 -

8c: White solid, mp 145-146 °C;  $R_f$  (5% methanol in methylene chloride): 0.62;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.10 (m, 10H), 6.90-6.75 (broad, 1H), 6.25 (d, 1H), 5.25-5.15 (m, 1H), 5.10 (s, 1H); 3.40-3.25 (m, 2H), 3.05-2.95 (dd, 1H), 2.80 (m, 1H), 2.65-2.50 (dd, 1H), 2.00 (m, 1H), 1.70-1.40 (m, 4H), 1.35-1.05 (m, 3H), 1.00-0.75 (m, 9H).


8d: White solid, mp 184-185 °C;  $R_f$  (5% methanol in methylene chloride): 0.50;  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.00 (m, 8H), 6.85-6.75 (broad, 1H), 6.15 (d, 1H), 5.20-5.10 (m, 1H), 4.90 (s, 1H), 3.40-3.25 (m, 2H), 2.75-2.65 (dd, 1H), 2.60-2.50 (m, 1H), 2.40-2.25 (dd, 1H), 2.00 (m, 1H), 1.70-1.55 (m, 2H), 1.40-1.20 (m, 2H), 1.15 (t, 3H), 0.90 (t, 3H), 0.80 (d, 3H), 0.70 (d, 3H).

8e: White solid, mp 157-158 °C;  $R_f$  (5% methanol in methylene chloride): 0.50;  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.20 (m, 5H), 6.85-6.75 (broad, 1H), 6.20 (m, 1H), 5.30-5.10 (m, 2H), 5.00 (d, 2H), 4.40-4.00 (m, 1H), 3.35-3.20 (m, 1H), 3.00-2.80 (m, 1H), 2.80-2.60 (m, 1H), 2.55-2.35 (m, 1H), 2.00-1.85 (m, 1H), 1.70-1.20 (m, 8H), 1.15-1.05 (m, 3H), 1.00-0.70 (m, 15H).

8f: White solid, mp 182-183 °C;  $R_f$  (5% methanol in methylene chloride): 0.70;  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.00 (m, 8H), 6.85-6.75 (broad, 1H), 6.15 (d, 1H), 5.25-5.15 (m, 1H), 4.90 (s, 1H), 3.40-3.25 (m, 2H), 2.75-2.65 (dd, 1H), 2.60-2.50 (m, 1H), 2.40-2.25 (dd, 1H), 1.80-1.60 (m, 4H), 1.45-1.20 (m, 2H), 1.15 (t, 3H), 0.90 (t, 6H), 0.80 (d, 3H), 0.70 (d, 3H).

The synthesis of compounds of general Formula 9-14 are summarized in Scheme II below:

SCHEME II

**Example 7: Synthesis of Intermediate 10**

To a stirring mixture of *trans*- $\beta$ -nitrostyrene (9, 5.25g, 0.035 mol) and silica gel (10g, 230-400 mesh) in chloroform (400 mL) and isopropanol (75 mL) at room temperature, was slowly added sodium borohydride (5.50g, 0.145 mol) over a period of 45 minutes. The reaction mixture was stirred for an additional 15 minutes and then carefully quenched with 10% hydrochloric acid (20 mL). Separated solid was filtered and washed with chloroform (50 mL). Combined filtrate and washing was washed with water (1 x 20 mL), brine (1 x 20 mL) and dried over anhydrous sodium sulfate. Solvent evaporation at reduced pressure gave a crude material which was purified by flash chromatography (silica gel, 8% ethyl acetate-hexane) to give 2.86 g of compound 10.

- 25 -

10: Colorless oil (spicy odor);  $R_f$  (10% ethyl acetate in hexane): 0.40;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.20 (m, 5H), 4.60 (t, 2H), 3.30 (t, 2H).

**Example 8****5 Synthesis of Intermediates 11a-b**

To a cooled ( $-78^\circ\text{C}$ ) solution of oxalyl chloride (2M) in methylene chloride (11.60 mL, 0.0232 mol) was added slowly dimethyl sulfoxide (3.65g, 3.32 mL, 0.0467 mol). The reaction mixture was stirred for 15 minutes. A solution of  
10 2-fluoroethanol (1.16g, 0.0181 mol) in methylene chloride (10 mL) was then slowly introduced into the reaction flask. After stirring for another 15 minutes, the reaction mixture was diluted with anhydrous methylene chloride (180 mL) and triethylamine (9.20g, 12.63 mL, 0.090 mol) was added to it.  
15 Stirring was continued for another 2 hours by which time temperature changed to room temperature. At this time, a solution of compound 10 (2.74g, 0.0181 mol) in anhydrous methylene chloride (10 mL) was added to the reaction mixture and stirring was continued overnight. The mixture was then  
20 washed with water (1 x 30 mL), 4% hydrochloric acid (3 x 20 mL), water (1 x 20 mL), saturated sodium bicarbonate solution (2 x 20 mL) and brine (1 x 20 mL). Drying over anhydrous sodium sulfate and solvent evaporation gave a crude material which was purified by flash chromatography  
25 (silica gel, 25% ethyl acetate-hexane) to give 11a and 11b as erythro / threo isomers. Combined yield was 3.01g. A general description of this procedure can be found in Imperiali, B. et al., *Tetrahedron Lett.* 27(2), 135, 1986 and in Revesz, L. et al., *Tetrahedron Lett.* 35(52), 9693, 1994.

30 11a: White solid, mp  $71-73^\circ\text{C}$ ;  $R_f$  (30% ethyl acetate in hexane): 0.46;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.10 (m, 5H), 4.90 (m, 1H), 4.60 (m, 1H), 4.50-4.30 (m, 2H), 3.45-3.25 (m, 2H), 2.70 (d, 1H).

11b: Colorless oil;  $R_f$  (30% ethyl acetate in hexane): 0.42;  
35  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.15 (m, 5H), 4.90 (m, 1H),

- 26 -

4.65 (m, 1H), 4.50 (m, 1H), 4.20 (m, 1H), 3.40-3.30 (m, 2H),  
2.90 (d, 1H).

**Example 9****Synthesis of Intermediates 12a-b**

- 5           A mixture of intermediate 11a ( 0.48g, 2.25 mmol),  
absolute ethanol (20 mL) and Raney-Nickel (catalytic) was  
hydrogenated (60 psi) in a Parr apparatus for 5 hours.  
Filtration through a celite pad and solvent evaporation gave  
0.41g of 12a which was used without further purification.  
10 Similar treatment of 11b (0.80g, 3.75 mmol) gave 0.51 g of  
12b.

12a: White solid, mp 64-67 °C; <sup>1</sup>H-NMR (300MHz, CDCl<sub>3</sub>) δ 7.40-  
7.10 (m, 5H), 4.70 (d, 1H), 4.50 (d, 1H), 3.90-3.70 (m, 1H),  
3.30-3.10 (m, 1H), 2.95 (dd, 1H), 2.60-2.45 (q, 1H), 2.20-  
15 1.70 (broad, 3H).

12b: White solid, mp 67-70 °C; <sup>1</sup>H-NMR (300MHz, CDCl<sub>3</sub>) δ 7.40-  
7.10 (m, 5H), 4.70 (d, 1H), 4.55 (d, 1H), 3.70-3.50 (m, 1H),  
3.20-3.00 (m, 1H), 2.95 (dd, 1H), 2.60-2.45 (q, 1H), 2.20-  
1.65 (broad, 3H).

20 **Example 10**  
**Synthesis of Intermediates 13a-c**

- These intermediates were generated as  
diastereomeric mixtures following the same synthetic  
procedure as described for the syntheses of the compounds  
25 7a-f. Thus, the coupling of 0.32g of 5b with 0.22g of 12b  
produced 0.30g of 13a. Similarly, 0.34g of 5d and 0.36g of  
5e yielded 0.14g and 0.25g of 13b and 13c respectively.

13a: Viscous oil; R<sub>f</sub> (5% methanol in methylene chloride):  
0.62; <sup>1</sup>H-NMR (300MHz, CDCl<sub>3</sub>) δ 7.30-7.00 (m, 10H), 6.10-5.80  
30 (2 sets of d, 1H), 4.40-3.70 (m, 5H), 3.50-3.30 (m, 1H),  
3.00-2.20 (m, 5H), 2.00-1.90 (m, 1H), 1.70-1.50 (m, 1H),  
1.30-1.15 (m, 2H), 1.00-0.60 (m, 9H).

- 27 -

13b: White solid, mp 150-155 °C (softening to melt);  $R_f$  (5% methanol in methylene chloride): 0.47;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-6.95 (m, 13H), 5.85-5.65 (2 sets of d, 1H), 4.80 (d, 1H), 4.60-4.20 (m 3H), 4.10-3.75 (m, 2H), 3.10-2.60 (m, 3H),  
5 2.50-2.15 (m, 2H), 1.30-1.10 (m, 1H), 1.00-0.75 (m, 2H),  
0.70-0.50 (m, 6H).

13c: Viscous oil;  $R_f$  (5% methanol in methylene chloride): 0.51;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.15 (m, 10H), 6.30-6.00 (m, 1H), 5.35-5.20 (m, 1H), 5.10 (q, 1H), 4.50-4.15 (m,  
10 4H), 4.10-3.80 (m, 2H), 3.00-2.40 (m, 5H), 1.80-1.00 (m, 6H), 1.00-0.70 (m, 12H).

#### Example 11 Synthesis of Fluoroketones 14a-c.

These compounds were generated as diastereomeric  
15 mixtures following the same synthetic procedure as described for the syntheses of the compounds 8a-f. Thus, the oxidation of 0.055g of 13a produced 0.028g of 14a. Similarly, 0.027g of 13b and 0.040g of 13c yielded 0.020g and 0.023g of 14b and 14c respectively.

20 14a: Viscous oil;  $R_f$  (30% ethyl acetate in hexane): 0.45;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.00 (m, 10H), 6.25-6.00 (2 sets of m, 1H), 5.10-4.55 (m, 3H), 3.50-3.40 (m, 1H), 3.20-2.90 (m, 2H), 2.80-2.50 (m, 2H), 2.45-2.25 (m, 1H), 2.10-1.90 (m, 1H), 1.80-1.60 (m, 2H), 1.50-1.20 (m, 2H), 1.00-0.60 (m,  
25 9H).

14b: White solid, mp 144-150 °C (softening to melt);  $R_f$  (30% ethyl acetate in hexane): 0.40;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.30-6.95 (m, 13H), 6.05-5.85 (2 sets of d, 1H), 5.00-4.45 (m 4H), 3.10-2.80 (m, 2H), 2.60-2.15 (m, 3H), 1.30-1.10 (m,  
30 1H), 1.00-0.75 (m, 2H), 0.70-0.50 (m, 6H).


14c: Viscous oil;  $R_f$  (30% ethyl acetate in hexane): 0.33;  $^1\text{H-NMR}$

- 28 -

NMR (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.10 (m, 10H), 6.25-6.05 (m, 1H), 5.20-4.60 (m, 6H), 4.40-4.20 (m, 1H), 3.20-2.40 (m, 5H), 1.80-1.00 (m, 6H), 1.00-0.70 (m, 12H).

The synthesis of compounds of general Formula 15 and 16 are summarized in Scheme III below:

SCHEME III



16 a)  $\text{R} = -(\text{CH}_2)_4\text{Ph}$

b)  $\text{R} = -(\text{S})-\text{CH}(\text{Et})\text{Ph}$

c)  $\text{R} = -\text{CH}(\text{Ph})_2$

d)  $\text{R} = \text{xanthen-9-yl}$

e)  $\text{R} = -(\text{S})-\text{CH}(\text{iBu})\text{NHCbz}$

**Example 12****Synthesis of Intermediates 15a-e: General Procedure**

To a cooled (0 °C) solution of 5a-e (0.0005-0.001 mol) in anhydrous N,N-dimethylformamide (3-4 mL) was added  
5 N-methylmorpholine (3 eqv.) followed by 1-HOBt (1 eqv.) and BOP (1 eqv.). The mixture was stirred for 15 minutes and to it was added (S)-leucinol (1.3-1.4 eqv.). The cooling bath was removed and the mixture was stirred overnight, poured into water (5 mL) and extracted into ethyl acetate (3 x 10  
10 mL). The organic layer was washed with 2% citric acid solution (2 x 5 mL), saturated sodium bicarbonate solution (2 x 5 mL), brine (1 x 5 mL) and dried over anhydrous sodium sulfate. Solvent evaporation under reduced pressure gave a crude material which was purified by flash chromatography  
15 (silica gel, 4-5% methanol-methylene chloride) to produce 15a-e in 40-60% yield.

15a: Viscous oil;  $R_f$  (5% methanol in methylene chloride): 0.40;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.10 (m, 5H), 5.85 (d, 1H), 3.85 (m, 1H), 3.60 (m, 1H), 3.50 (m, 1H), 3.00-2.80 (m, 20 2H), 2.70 (m, 1H), 2.60 (m, 2H), 2.50-2.30 (m, 3H), 1.70-1.50 (m, 8H), 1.45-1.20 (m, 2H), 1.00-0.80 (m, 12H).

15b: White gum;  $R_f$  (5% methanol in methylene chloride): 0.36;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.10 (m, 5H), 5.85 (m, 1H), 4.00-3.80 (m, 1H), 3.70-3.40 (m, 3H), 3.00-2.70 (m, 25 2H), 2.50-2.30 (td, 1H), 2.00 (m, 1H), 1.80-1.20 (m, 8H), 1.00-0.70 (m, 15H).

15c: White solid, mp 110-112 °C;  $R_f$  (5% methanol in methylene chloride): 0.45;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.10 (m, 10H), 5.85 (d, 1H), 5.10 (s, 1H), 3.85 (m, 1H), 3.60 (m, 1H), 3.50 30 (m, 1H), 3.00 (q, 1H), 2.80-2.70 (m, 2H), 2.30 (dd, 1H), 1.60-1.00 (m, 6H), 1.00-0.80 (m, 12H).

15d: White solid, mp 168-169 °C;  $R_f$  (5% methanol in methylene chloride): 0.55;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.00 (m, 8H), 5.70 (d, 1H), 4.90 (s, 1H), 3.85 (m, 1H), 3.60 (m, 1H), 3.50

- 30 -

(m, 1H), 2.80 (t, 1H), 2.70 (q, 1H), 2.50 (m, 1H), 2.30 (dd, 1H), 1.60 (m, 1H), 1.50-1.20 (m, 5H), 1.00-0.60 (4 sets of doublets, 12H).

15e: White solid, mp 65-80 °C (softening to melt);  $R_f$  (5% methanol in methylene chloride): 0.30;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.20 (m, 5H), 5.85 (m, 1H), 5.50-5.30 (m, 1H), 5.20-5.00 (m, 2H), 4.40-4.20 (m, 1H), 4.00-3.80 (m, 1H), 3.60-3.40 (m, 2H), 3.10-2.90 (m, 1H), 2.80-2.60 (m, 1H), 2.50-2.40 (m, 1H), 1.80-1.10 (m, 10H), 1.00-0.87 (m, 18H).

#### 10 Example 13

##### Synthesis of Aldehydes 16a-e: General Procedure

To a cooled (0°C) solution of alcohol 15a-e (0.05-0.10 mmol) in anhydrous methylene chloride (2-3 mL) and anhydrous dimethyl sulfoxide (2-3 mL) was added triethylamine (3.00 eqv.). Sulfur trioxide-pyridine complex (3.00 eqv.) was slowly added to the stirred mixture over a period of 5 minutes and the ice-bath was removed. The mixture was stirred for another 1 hour, poured into water (10 mL) and extracted into ether (3x10 mL). The organic layer was washed with 2% citric acid solution (2 x 5 mL), saturated sodium bicarbonate solution (2 x 5 mL), brine (1 x 5 mL) and dried over anhydrous magnesium sulfate. Solvent evaporation gave a residue which was washed with n-pentane (5-8 mL) and dried under vacuum to produce the desired compound 16a-e in 50-60% yield. A general description of this procedure can be found in Luly, J.R. et al., J. Org. Chem. 52, 1487-1492 (1987).

16a: White solid, mp 64-65 °C;  $R_f$  (30% ethyl acetate in hexane): 0.48;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  9.55 (s, 1H), 7.30-7.10 (m, 5H), 6.10 (d, 1H), 4.50 (m, 1H), 3.00-2.80 (m, 2H), 2.60 (m, 2H), 2.40 (m, 3H), 1.80-1.60 (m, 8H), 1.50-1.10 (m, 2H), 1.00-0.80 (m, 12H).

16b: Viscous liquid;  $R_f$  (30% ethyl acetate in hexane): 0.52;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  9.55 and 9.45 (2 singlets, 3:2, 1H),



- 31 -

7.40-7.10 (m, 5H), 6.10 (m, 1H), 4.60-4.30 (2 sets of multiplet, 3:2, 1H), 3.50 (t, 1H), 3.00-2.70 (m, 2H), 2.50-2.30 (td, 1H), 2.00 (m, 1H), 1.80-1.20 (m, 7H), 1.00-0.70 (m, 15H).

5

16c: White solid, mp 85-95 °C (softening to melt);  $R_f$  (30% ethyl acetate in hexane): 0.45;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  9.55 (s, 1H), 7.40-7.10 (m, 10H), 6.10 (d, 1H), 5.10 (s, 1H), 4.50 (m, 1H), 3.00 (q, 1H), 2.90-2.70 (m, 1H), 2.60  
10 (dd, 1H), 1.80-1.00 (m, 6H), 1.00-0.80 (m, 12H).


16d: White solid, mp 115-125 °C (softening to melt);  $R_f$  (30% ethyl acetate in hexane): 0.45;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  9.50 (s, 1H), 7.40-7.00 (m, 8H), 6.00 (d, 1H), 4.90 (s, 1H), 4.40 (m, 1H), 2.80-2.65 (q, 1H), 2.60 (m, 1H), 2.30 (dd,  
15 1H), 1.80-1.20 (m, 6H), 1.00-0.60 (4 sets of doublets, 12H).

16e: White gum;  $R_f$  (30% ethyl acetate in hexane): 0.30;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  9.55 and 9.50 (2 singlets, 10;1, 1H), 7.40-7.20 (m, 5H), 6.15-5.90 (m, 1H), 5.30-5.00 (m, 3H), 4.50-4.10 (m, 2H), 3.10-2.90 (m, 1H), 2.80-2.60 (m, 1H),  
20 2.50-2.40 (m, 1H), 1.80-1.10 (m, 9H), 1.00-0.70 (m, 18H).

The synthesis of compounds 16f-g, and of general Formula 17-23, are summarized in Scheme IV below:

- 32 -

## SCHEME IV



## Example 14

## Synthesis of Intermediate 18

A mixture of 4-methylvaleric acid (17, 12.31g, 0.106 mol), benzyl alcohol (10.88g, 0.10 mol) and p-toluenesulfonic acid monohydrate (1.00g) in benzene (100 mL) was refluxed using a Dean-Stark water separator for 2 hours. After cooling, benzene was removed and the mixture was diluted with ether (50 mL), washed successively with saturated NaHCO<sub>3</sub> solution (2 x 20 mL), brine (1 x 20 mL), dried (MgSO<sub>4</sub>), and concentrated to give the compound 18 (20.00g).

- 33 -

18: Colorless oil;  $R_f$  (5% ethyl acetate in hexane): 0.46;  $^1\text{H}$ -NMR (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.20 (m, 5H), 5.10 (s, 2H), 2.35 (t, 2H), 1.55 (m, 3H), 0.90 (d, 6H).

#### Example 15

##### 5 Synthesis of Intermediate 19

To a cooled (-78 °C) solution of lithium diisopropylamide (12 mmol) in a mixture of tetrahydrofuran (20 mL) and hexane (4.8 mL) (obtained *in situ* from diisopropylamine and *n*-butyllithium) was added slowly the  
10 compound 18 (2.06g, 10 mmol) in anhydrous tetrahydrofuran (8 mL). The mixture was stirred for 30 minutes and *tert*-butyl bromoacetate (2.34g, 12 mol) in hexamethylphosphoramide (2.09 mL) was added to the flask. The mixture was stirred at -78 °C for 30 minutes, slowly brought to 0 °C over a  
15 period of 2h and quenched by the cautious addition of saturated ammonium chloride (50 mL). The mixture was extracted into ether (3 x 50 mL) and the combined organic layer was washed with brine (1 x 25 mL), dried over anhydrous  $\text{MgSO}_4$  and concentrated to give a crude material.  
20 Purification of this material by flash chromatography over silica using 2% ethyl acetate in hexane as an eluant gave 2.00g of racemic diester 19.

19: Colorless oil;  $R_f$  (5% ethyl acetate in hexane): 0.34;  $^1\text{H}$ -NMR (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.30 (m, 5H), 5.15 (q, 2H), 2.90  
25 (m, 1H), 2.60 (q, 1H), 2.35 (q, 1H), 1.60-1.20 (m, 3H), 1.40 (s, 9H), 1.00-0.80 (2 sets of d, 6H).

#### Example 16

##### Synthesis of Intermediate 20

A mixture of diester 19 (0.54g, 1.673 mmol) and  
30 90% trifluoroacetic acid (1.5 mL) in methylene chloride (3 mL) was stirred at room temperature for 1.5 hours. Solvent and excess reagent were removed under reduced pressure to give 0.44g of a crude product. An  $^1\text{H}$ -NMR ( $\text{CDCl}_3$ ) of this crude product showed no detectable peak for the *tert*-butyl  
35 ester moiety at  $\delta$  1.40. This material was used without

further purification.

#### Example 17

##### Synthesis of Intermediates 21a-b

To a stirred mixture of 20 (0.95g, 3.60 mmol) and  
5 1,2,3,4-tetrahydroisoquinoline (0.48g, 3.60 mmol) in  
anhydrous methylene chloride (8 mL) at room temperature, was  
added triethylamine (0.80g, 7.92 mmol) followed by BOP-Cl  
(0.92g, 3.60 mmol). The mixture was stirred overnight,  
diluted with methylene chloride (10 mL) and washed  
10 successively with water (1 x 5 mL), saturated NaHCO<sub>3</sub> (2 x 5  
mL) and brine (1 x 5 mL). Drying over Na<sub>2</sub>SO<sub>4</sub> and solvent  
evaporation gave a crude material which was purified by  
flash chromatography over silica using 20% ethyl acetate in  
hexane to give 0.89g of racemic 21a.

15 Similar treatment of Compound 20 (0.44g, 1.67  
mmol) with 0.27g of 1-phenylpiperazine yielded 0.45g of  
racemic Compound 21b. A general description of this  
procedure can be found in Tung, R.D. et al., J. Am. Chem.  
Soc. 107, 4342-4343 (1985).

20 21a: Colorless oil; R<sub>f</sub> (20% ethyl acetate in hexane): 0.70;  
<sup>1</sup>H-NMR (300MHz, CDCl<sub>3</sub>) δ 7.40-7.00 (m, 9H), 5.10 (q, 2H),  
4.70 (q, 2H), 3.90-3.60 (m, 2H), 3.20-3.00 (m 1H), 2.90-2.70  
(m, 3H), 2.50-2.40 (m, 1H), 1.70-1.50 (m, 2H), 1.40-1.30 (m,  
1H), 1.00-0.80 (m, 6H).

25 21b: White solid, mp 90-105 °C (softening to melt); R<sub>f</sub> (30%  
ethyl acetate in hexane): 0.31; <sup>1</sup>H-NMR (300MHz, CDCl<sub>3</sub>) δ  
7.40-7.20 (m, 7H), 7.00-6.90 (t, 3H), 5.20-5.00 (q, 2H)  
3.80-3.55 (m, 4H), 3.20-3.00 (m, 5H), 2.80 (q, 1H), 2.40  
(dd, 1H), 1.60 (m, 2H), 1.30 (m, 1H), 1.00-0.80 (2 sets of  
30 d, 6H).

#### Example 18

##### Synthesis of Intermediates 22a-b

A mixture of the benzyl ester 21a (0.88g, 2.32  
mmol) and 10% Pd-C (0.30g, Degussa, H<sub>2</sub>O content 50%) in

- 35 -

methanol (30 mL) was hydrogenated for 2 hours in a Parr apparatus (40-30 psi). The reaction mixture was filtered through a celite pad and concentrated to give 0.67g of the racemic acid 22a.

- 5                Similar treatment of 0.30g of 21b produced 0.23g of racemic acid 22b.

22a: Pale yellow solid, mp 95-105 °C (softening to melt); <sup>1</sup>H-NMR (300MHz, CDCl<sub>3</sub>) δ 7.40-7.00 (m, 4H), 5.00- 4.80 (q, 2H), 4.00-3.60 (m, 2H), 3.20-3.00 (m 1H), 2.90-2.70 (m, 3H),  
10 2.60-2.40 (m, 1H), 1.80-1.60 (m, 2H), 1.40-1.30 (m, 1H), 1.00-0.80 (m, 6H).

22b: Pale yellow oil; <sup>1</sup>H-NMR (300MHz, CDCl<sub>3</sub>) δ 7.40-7.20 (m, 2H), 7.00-6.90 (t, 3H), 3.80-3.55 (m, 4H), 3.20-3.10 (m, 4H), 3.00 (m, 1H), 2.80 (q, 1H), 2.50 (dd, 1H), 1.60 (m,  
15 1H), 1.30 (m, 2H), 1.00-0.80 (m, 6H).

#### Example 19 Synthesis of Intermediates 23a-b

These compounds were generated as separated diastereomeric mixtures following the same synthetic  
20 procedures as described for the syntheses of the compounds 15a-e. Thus 0.23g of 22a generated 0.20g of 23a and 0.32g of 22b produced 0.22g of 23b.

23a: Isomer I: White gum, R<sub>f</sub> (ethyl acetate): 0.62; <sup>1</sup>H-NMR (300MHz, CDCl<sub>3</sub>) δ 7.30-7.10 (m, 9H), 6.60 (d, 1H), 4.70-4.50  
25 (q, 2H), 4.50 (s, 1H), 4.00 (m, 1H), 3.90-3.50 (m, 4H), 3.00-2.60 (m, 6H), 2.40-2.30 (m, 1H), 1.70-1.60 (m, 1H), 1.60-1.40 (m, 1H), 1.20 (m, 1H), 1.00-0.80 (m, 6H).

23a: Isomer II: White gum; R<sub>f</sub> (ethyl acetate): 0.44; <sup>1</sup>H-NMR (300MHz, CDCl<sub>3</sub>) δ 7.30-7.00 (m, 9H), 6.00 (m, 1H), 4.80-4.50  
30 (q, 2H), 4.60 (s, 1H), 4.30 (m, 1H), 3.90-3.40 (m, 4H), 3.00-2.60 (m, 6H), 2.40-2.20 (m, 1H), 1.60-1.50 (m, 1H), 1.30-1.20 (m, 1H), 1.00 (m, 1H), 0.80-0.60 (m, 6H).

- 36 -

23b: Isomer I: Viscous oil;  $R_f$  (70% ethyl acetate in hexane): 0.28;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.30-7.20 (t, 2H), 7.00-6.90 (t, 3H), 6.25 (d, 1H), 3.90 (m, 1H), 3.70 (m, 2H), 3.60 (m, 4H), 3.20-3.10 (m, 5H), 2.90 (m, 1H), 2.80 (q, 1H), 2.40 (dd, 1H), 1.80-1.20 (m, 6H), 1.00-0.80 (m, 12H).

23b: Isomer II: Viscous oil;  $R_f$  (70% ethyl acetate in hexane): 0.20;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.30-7.20 (m, 2H), 7.00-6.90 (t, 3H), 5.75 (d, 1H), 4.15-4.00 (m, 1H), 3.80-3.60 (m, 6H), 3.40-3.30 (q, 1H), 3.20-3.10 (m, 4H), 2.90 (q, 1H), 2.70 (m, 1H), 2.35 (dd, 1H), 1.60-1.10 (m, 6H), 1.00-0.80 (m, 12H).

#### Example 20

##### Synthesis of Aldehydes 16f-g.

These compounds were synthesized following the same procedure as described for the syntheses of the compounds 16a-e. Yield was 50-60%.

16f: Isomer I: White solid, mp 45-65 °C (softening to melt);  $R_f$  (70% ethyl acetate in hexane): 0.58;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  9.60 (s, 1H),  $\delta$  7.30-7.10 (m, 9H), 6.75 (d, 1H), 4.70-4.50 (m, 3H), 3.90-3.50 (m, 2H), 3.20-2.60 (m, 6H), 2.40-2.30 (m, 1H), 1.80-1.20 (m, 3H), 1.00-0.80 (m, 6H).

16f: Isomer II: White gum,  $R_f$  (70% ethyl acetate in hexane): 0.41;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  9.50 (d, 1H), 7.40-7.10 (m, 9H), 6.60 (t, 1H), 4.70-4.50 (m, 3H), 3.90-3.50 (m, 2H), 3.20-2.60 (m, 6H), 2.40-2.30 (m, 1H), 1.70-1.10 (m, 3H), 1.00-0.80 (m, 6H).


16g: Isomer I: White gum,  $R_f$  (70% ethyl acetate in hexane): 0.57;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  9.55 (s, 1H), 7.30 (d, 2H), 6.90 (m, 3H), 6.45 (d, 1H), 4.40 (m, 1H), 3.80-3.60 (m, 4H), 3.15 (m, 4H), 3.00 (m, 1H), 2.80 (q, 1H), 2.40-2.30 (dd, 1H), 1.80-1.60 (m, 4H), 1.45 (m, 1H), 1.20 (m, 1H), 1.00-0.80 (m, 12H).

- 37 -

16g: Isomer II: White gum,  $R_f$  (70% ethyl acetate in hexane): 0.42;  $^1\text{H-NMR}$  (300MHz,  $\text{CDCl}_3$ )  $\delta$  9.40 (s, 1H), 7.20 (m, 2H), 6.80 (m, 3H), 6.45 (d, 1H), 4.35 (m, 1H), 3.80-3.50 (m, 4H), 3.15 (m, 4H), 3.00 (m, 1H), 2.80 (q, 1H), 2.40-2.30 (dd, 5 1H), 1.80-1.60 (m, 4H), 1.45 (m, 1H), 1.20 (m, 1H), 1.00-0.80 (m, 12H).

The synthesis of compounds of Formula 26-32 are summarized in Scheme V below:

SCHEME V



## Example 21

## 10 Synthesis of Intermediates 26-27

A mixture of isobutyl amine (24, 7.36g), glyoxylic acid (25, 5g), water (30mL) and 10% Pd-C(1g) was hydrogenated (40psi) in a Parr apparatus for 4 hours.

- 38 -

Filtration and concentration of the reaction mixture at high vacuum gave compound 26 in quantitative yield. A sample of this material (2.48g) was dissolved in acetonitrile-water (1:1, 40mL), the solution was cooled to 0°C, and to it was  
5 added 5.20g of N-(benzyloxycarbonyloxy)succinimide in portions. The ice-bath was removed and the reaction mixture was stirred for an additional hour. Acetonitrile was removed in the rotavapor, base was added to pH 9-10 and the layer was washed several times with a mixture of ether and  
10 hexane (1:1). The aqueous layer was then acidified (solid citric acid) to pH 3-4 and extracted into ethyl acetate (3 x 40mL). Drying (MgSO<sub>4</sub>) and solvent evaporation gave compound 27 which was used without further purification.

27: White gum; <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) shows 2 rotamers; δ  
15 7.40-7.20 (m, 5H), 5.20 and 5.15 (2 singlets, 2H), 4.10 and 4.00 (2 singlets, 2H), 3.15 (2 overlapping doublets, 2H), 2.90 (m, 1H), 0.90 (m, 6H).

#### Synthesis of Intermediate 28

This material was synthesized following the same  
20 general procedure as described above for the synthesis of compounds 2a-e. Thus, 5.06g of compound 27 was converted to 3.32g of compound 28.

28: Colorless oil; R<sub>f</sub> (20% ethyl acetate in hexane); 0.50;  
<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) shows 2 rotamers; δ 7.40-7.20 (m,  
25 5H), 5.15 and 5.10 (2 singlets, 2H), 4.20 and 4.15 (2 singlets, 2H), 3.40 and 3.30 (2 singlets, 2H), 3.15 (2 overlapping doublets, 2H), 1.90 (m, 1H), 1.50 and 1.40 (2 singlets, 9H), 0.90 (m, 6H).

#### Synthesis of Intermediate 29

30 This material was synthesized following the same general procedure as described above for the synthesis of compounds 4a-e. Thus, 3.30g of compound 28 was converted to 1.41g of compound 29.



- 39 -

29: Viscous oil;  $R_f$  (20% ethyl acetate in hexane); 0.50;  $^1\text{H}$ -NMR (300 MHz,  $\text{CDCl}_3$ ) shows 2 rotamers;  $\delta$  7.40-7.20 (m, 5H), 5.20-5.10 (2 sets of dd, 2H), 4.20-3.90 (m, 3H), 3.70 and 3.60 (2 singlets, 3H), 3.20-1.10 (a series of multiplets, 8H), 0.90 (m, 12H).

#### Synthesis of Intermediate 30

This material was synthesized following the same general procedure as described above for the synthesis of compounds 5a-e. Thus, 0.52g of compound 29 was converted to 0.50g of compound 30.  $^1\text{H}$ -NMR (300 MHz,  $\text{CDCl}_3$ ) shows absence of rotameric methyl peaks at  $\delta$  3.70 and 3.60.

#### Synthesis of Intermediate 31

This material was synthesized following the same general procedure as described above for the synthesis of compounds 15 a-d. Thus, 0.49g of compound 30 was converted to 0.44g of compound 31.

31: White gum;  $R_f$  (5% methanol in methylene chloride); 0.52;  $^1\text{H}$ -NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.20 (m, 5H), 5.90 and 5.70 (2 sets of d, 1H), 5.20-5.00 (2 sets of dd, 2H), 4.20-3.40 (3 sets of m, 3H), 3.20-1.10 (a series of multiplets, 15H), 0.90 (m, 18H).

#### Synthesis of Aldehyde 32

This material was synthesized following the same general procedure as described above for the synthesis of compounds 16a-d. Thus, 0.43g of compound 31 was converted to 0.20g of compound 32.

32: White solid, mp 93-95°C;  $R_f$  (5% methanol in methylene chloride): 0.53;  $^1\text{H}$ -NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  9.55 (s, 1H), 7.40-7.20 (m, 5H), 6.15 and 6.00 (2 sets of d, 1H), 5.20-5.00 (2 sets of dd, 2H), 4.50-3.70 (3 sets of m, 3H), 3.20-1.10 (a series of multiplets, 12H), 0.90 (m, 18H).

**Example 22A****Inhibition and Rate of Inactivation of Cysteine Protease Activity**

To evaluate inhibitory activity, stock solutions (40 times concentrated) of each compound to be tested were prepared in 100% anhydrous DMSO and 5  $\mu$ L of each inhibitor preparation were aliquoted into each of three wells of a 96-well plate. Calpain I, prepared by a modification of the method of W. J. Lee et al. (*Biochem. Internatl.* 22: 163-171 (1990)), was diluted into assay buffer (i.e., 50mM Tris, 50mM NaCl, 1mM EDTA, 1mM EGTA, and 5mM-mercaptoethanol, pH 7.5 including 0.2mM Succ-Leu-Tyr-MNA) and 175  $\mu$ L aliquoted into the same wells containing the independent inhibitor stocks as well as to positive control wells containing 5  $\mu$ L DMSO, but no compound. To start the reaction, 20  $\mu$ L of 50 mM CaCl<sub>2</sub> in assay buffer was added to all wells of the plate, excepting three, which were used as background signal baseline controls. Substrate hydrolysis was monitored every 5 minutes for a total of 30 minutes using a Fluoroskan II fluorescence plate reader. Substrate hydrolysis in the absence of inhibitor was linear for up to 15 minutes.

Inhibition of calpain I activity was calculated as the percent decrease in the rate of substrate (S) hydrolysis in the presence of inhibitor (<sub>i</sub>) relative to the rate in its absence (<sub>o</sub>). Comparison between the inhibited and control rates was made within the linear range for substrate hydrolysis. For screening, compounds were tested at 10  $\mu$ M. Compounds having 50% inhibition at 10  $\mu$ M were considered active. The IC<sub>50</sub>s of inhibitors (concentration yielding 50% inhibition) were determined from the percent decrease in the rates of substrate hydrolysis in the presence of five to seven different concentrations of the test compound. The results were plotted as % inhibition versus log inhibitor concentration and the IC<sub>50</sub> was calculated from linear regression of the data. Apparent second order rate constants were determined from analysis of reaction progress curves under pseudo-first order conditions. Each

- 41 -

determination represents the means of three or more independent single cuvette analyses continually monitored via a Perkin-Elmer LS50B spectrofluorimeter. The rate of inhibition of hydrolysis was obtained by fitting the curve  
5 to the exponential equation (1):

$$y = Ae^{-(K_{obs} \cdot t)} + B \quad (1)$$

where y is the product formed at time t.  $K_{obs}$  is the pseudo-first order rate constant for inactivation. A and B are constants. A, the amplitude of the reaction, is given by  
10  $[P_o - P_\infty]$  and B ( $= P_\infty$ ) is the maximal product formed when the reaction is complete. The apparent second order rate constant  $k_{app}$  was determined as  $K_{obs}/[I]$ . This was corrected for the presence of substrate to give the second order rate constant  $k_2$  according to equation (2):

$$15 \quad k_2 = k_{app} (1 + [S] / K_m) \quad (2)$$

To demonstrate activity against two other cysteine proteases, cathepsin B (Calbiochem, cat#219364) and cathepsin L (Calbiochem, cat#219402), assays were performed substantially the same as outlined above except that the  
20 cathepsin B and cathepsin L were diluted into a different assay buffer consisting of 50mM sodium acetate (pH 6.0)/1mM EDTA/1mM dithiothreitol and the substrate used was Cbz-Phe-Arg-AMC (Bachem cat# I-1160; 0.1mM for cathepsin B; 0.006mM for cathepsin L). Additionally, the order of  
25 reagents added to the plate was altered because both enzymes are constitutively active. Following inhibitor addition to the plates, appropriate 2x concentrated stock dilutions of the enzyme preparations were made in assay buffer and 100ul added to each well. The assay was initiated by addition of  
30 100ul of 2x concentrated stock dilution of substrate in assay buffer. Substrate hydrolysis was monitored using a Fluoroskan II (ex=390 nm; em=460 nm). Results are presented in Table II.

**Example 22B****Inhibition of Serine Protease Activity**

To demonstrate activity against the serine protease  $\alpha$ -chymotrypsin (Sigma Chem. Co. Cat. #C-3142) the protocol of Example 22A was followed except that the enzyme was diluted into assay buffer consisting of 50mM Hepes (pH 7.5)/0.5M NaCl and the final substrate concentration used was 0.03mM Succ-Ala-Ala-Pro-Phe-AMC (Bachem, Inc. Cat. #I-1465). Additionally, because  $\alpha$ -chymotrypsin is not a calcium sensitive enzyme and is constitutively active, following addition of inhibitor stocks to the 96 well plates, 100 $\mu$ l of a 2-fold concentrated stock of enzyme in dilution buffer was first added and the reaction started by addition of 100 $\mu$ l of a 2-fold concentrated stock of substrate in assay buffer. Substrate hydrolysis was monitored every 5 minutes up to 30 minutes using a Fluoroskan II (em=390nm ex=460nm). Results, expressed as inhibition of  $\alpha$ -chymotrypsin at 10  $\mu$ M, are presented in Table II.

Inhibition of thrombin (Sigma Chem. Co. Cat. #T-7009) was evaluated as described for chymotrypsin except that the assay was performed in 50 mM Tris, 10 mM CaCl<sub>2</sub>, pH 7.5 and the substrate was 25  $\mu$ M Bz-Phe-Val-Arg-AMC (Bachem cat#I-1080). Results are presented in Table II.

Table II

Compnd.	Chemical Name	Calpain IC50 (nM)	Calpain Inactivation Rates (M-1s-1)	Cat B %I @ 1 uM	Cat L %I @ 1 uM	Thrombin %I @ 10 uM	Chymo- trypsin %I @
32	Z-N(iBu)CH <sub>2</sub> COCH <sub>2</sub> CH(iBu)CONH-Leu-H	71		97	100	0	53
16e	Z-Leu-Psi[COCH <sub>2</sub> ]Leu-Leu-H	12					
16a	Ph(CH <sub>2</sub> ) <sub>2</sub> COCH <sub>2</sub> CH(iBu)CO-Leu-H	138		97	100	0	61
16c	Ph <sub>2</sub> CHCOCH <sub>2</sub> CH(iBu)CO-Leu-H	50		97	100	1	62
16d	Xanthene-COCH <sub>2</sub> CH(iBu)CO-Leu-H	25		76	100	25	98
16b	CH <sub>3</sub> CH <sub>2</sub> CH(Ph)COCH <sub>2</sub> CH(iBu)CO-Leu-H	55		99	100	0	21
8f	Xanthene-CO(CH <sub>2</sub> CH(iBu)CO-Leu-CONH- Xanthene-COCH <sub>2</sub> CH(iBu)CO-Phe-CH <sub>2</sub> F	130	75600	98	100	13	93
14b	Xanthene-COCH <sub>2</sub> CH(iBu)CO-Phe-CH <sub>2</sub> F	485		78	100	9	98
8d	Xanthene-COCH <sub>2</sub> CH(iBu)CO-Abu-CONH- CH <sub>2</sub> CH <sub>2</sub> CH(Ph)COCH <sub>2</sub> CH(iBu)CO-Phe-CH <sub>2</sub> F	1725	5800	100	100	0	33
14a	Ph <sub>2</sub> CHCOCH <sub>2</sub> CH(iBu)CO-Abu-CONH- CH <sub>2</sub> CH <sub>2</sub> CH(Ph)COCH <sub>2</sub> CH(iBu)CO-Abu-CONH- CH <sub>2</sub> CH <sub>2</sub> CH(Ph)COCH <sub>2</sub> CH(iBu)CO-Abu-CONH- Z-Leu-CH <sub>2</sub> CH(iBu)CO-Phe-CH <sub>2</sub> F	6685	16800	84	98	0	6
8b	Ph(CH <sub>2</sub> ) <sub>4</sub> COCH <sub>2</sub> CH(iBu)CO-Abu-CONH- Z-Leu-CH <sub>2</sub> CH(iBu)CO-Abu-CONH- Z-Leu-CH <sub>2</sub> CH(iBu)CO-Abu-CONH- Z-Leu-CH <sub>2</sub> CH(iBu)CO-Abu-CONH- Ph-Piperazine-COCH <sub>2</sub> CH(iBu)CO-Leu-H	8440		10	81	0	0
8e	Ph-Piperazine-COCH <sub>2</sub> CH(iBu)CO-Leu-H	380		100	95	0	0
16g-I	Ph-Piperazine-COCH <sub>2</sub> CH(iBu)CO-Leu-H	227		100	97	0	0
16g-II	Ph-Piperazine-COCH <sub>2</sub> CH(iBu)CO-Leu-H	4500		67	35	0	0
16f-I	2-THIQ-COCH <sub>2</sub> CH(iBu)CO-Phe-H	28		100	96	0	39
16f-II	2-THIQ-COCH <sub>2</sub> CH(iBu)CO-Phe-H (Diastereomer)	1000		71	52	0	12


It is intended that each of the patents, publications, and other published documents mentioned or referred to in this specification be herein incorporated by reference in their entirety.

5           As those skilled in the art will appreciate, numerous changes and modifications may be made to the preferred embodiments of the invention without departing from the spirit of the invention. It is intended that all such variations fall within the scope of the invention.

- 45 -


## WHAT IS CLAIMED IS:

1. A compound of the formula:



wherein:


- 5 Q is aryl having from about 6 to about 14 carbons, heteroaryl having from about 6 to about 14 ring atoms, aralkyl having from about 7 to about 15 carbons, alkyl having from 1 to about 10 carbons, said alkyl groups being optionally substituted with one or more J groups,
- 10 heteroalkyl having from 2 to about 7 carbons, arylheteroalkyl wherein the aryl portion can be unfused or fused with the heteroalkyl ring, alkoxy having from 1 to about 10 carbons, aralkyloxy having from about 7 to about 15 carbons, a carbohydrate moiety optionally containing one or
- 15 more alkylated hydroxyl groups, xanthene-9-yl, CH(*i*-C<sub>4</sub>H<sub>9</sub>)NHCbz, CH<sub>2</sub>N(*i*-C<sub>4</sub>H<sub>9</sub>)Cbz, or Formula II or III:



II

III

- 20 Y has the formula:



wherein:

R<sup>1</sup> and R<sup>2</sup> are independently H, alkyl having from one to

- 46 -

about 14 carbons, cycloalkyl having from 3 to about 10 carbons, or a natural or unnatural side chain of an L-amino acid, said alkyl and cycloalkyl groups being optionally substituted with one or more J groups;

5 J is halogen, lower alkyl, aryl, heteroaryl, amino optionally substituted with one to three aryl or lower alkyl groups, guanidino, alkoxycarbonyl, aralkoxycarbonyl, alkoxy, hydroxy, or carboxy; and

G is hydrogen;  $C(O=O)NR^3R^4$ ;  $CH_2R^5$  or  $C(=O)OR^3$ ;

10 wherein:

$R^3$  and  $R^4$  are each independently hydrogen, alkyl having from 1 to about 10 carbons, said alkyl groups being optionally substituted with one or more J groups, aryl having from about 6 to about 14 carbons, and aralkyl having  
15 from about 7 to about 15 carbons; and

$R^5$  is halogen;

with the proviso that if G is hydrogen and Q is alkyl substituted with J, and said J is an  $\alpha$ -amino group, then the  $\alpha$ -amino nitrogen must be tertiary.

20 2. The compound of claim 1 wherein  $R^2$  is isobutyl.

3. The compound of claim 1 wherein  $R^1$  is isobutyl, benzyl or ethyl.

4. The compound of claim 1 wherein G is hydrogen,  $-C(=O)NHC_2H_5$ , or  $-CH_2F$ .

25 5. The compound of claim 1 wherein  $R^2$  is isobutyl,  $R^1$  is isobutyl, benzyl or ethyl, and G is hydrogen,  $-C(=O)NHC_2H_5$ , or  $-CH_2F$ .

6. The compound of claim 1 wherein Q is  $-(CH_2)_4-C_6H_5$ .

30 7. The compound of claim 1 wherein Q is  $-CH(C_2H_5)(C_6H_5)$ .



- 47 -

8. The compound of claim 7 wherein Q is  
- (S) - CH(C<sub>2</sub>H<sub>5</sub>) (C<sub>6</sub>H<sub>5</sub>) .


9. The compound of claim 1 wherein Q is diphenylmethyl.

10. The compound of claim 1 wherein Q is  
5 xanthen-9-yl.

11. The compound of claim 1 wherein Q is  
-CH(*i*-C<sub>4</sub>H<sub>9</sub>)NHCBz.

12. The compound of claim 1 wherein Q is  
- (S) - CH(*i*-C<sub>4</sub>H<sub>9</sub>)NHCBz.

10 13. The compound of claim 1 wherein Q has the formula:



14. The compound of claim 5 wherein Q is  
- (CH<sub>2</sub>)<sub>4</sub>-C<sub>6</sub>H<sub>5</sub>.

15. The compound of claim 5 wherein Q is  
-CH(C<sub>2</sub>H<sub>5</sub>) (C<sub>6</sub>H<sub>5</sub>) .

15 16. The compound of claim 5 wherein Q is  
- (S) - CH(C<sub>2</sub>H<sub>5</sub>) (C<sub>6</sub>H<sub>5</sub>) .

17. The compound of claim 5 wherein Q is diphenylmethyl.


18. The compound of claim 5 wherein Q is  
xanthen-9-yl.

20 19. The compound of claim 5 wherein Q is  
-CH(*i*-C<sub>4</sub>H<sub>9</sub>)NHCBz.


- 48 -

20. The compound of claim 5 wherein Q is  
- (S) -CH(*i*-C<sub>4</sub>H<sub>9</sub>)NHCbz.

21. The compound of claim 5 wherein Q has the formula:




22. A compound of the formula:



wherein:

Q is -CH(R<sup>6</sup>)-NH(R<sup>7</sup>);

Y has the formula:



15 R<sup>1</sup>, R<sup>2</sup> and R<sup>6</sup> are independently H, alkyl having from one to about 14 carbons, cycloalkyl having from 3 to about 10 carbons, or a natural or unnatural side chain of an L-amino acid, said alkyl and cycloalkyl groups being optionally substituted with one or more J groups;

J is halogen, lower alkyl, aryl, heteroaryl, amino optionally substituted with one to three aryl or lower alkyl groups, guanidino, alkoxycarbonyl, alkoxy, hydroxy, or carboxy; and

20 R<sup>7</sup> is a protecting group.

23. The compound of claim 22 wherein R<sup>2</sup> is selected from the group consisting of alkyl and a natural or unnatural

- 49 -

side chain of an L-amino acid.

24. The compound of claim 23 wherein R<sup>1</sup> is isobutyl.
25. The compound of claim 23 wherein R<sup>1</sup> is benzyl.
26. The compound of claim 23 wherein R<sup>1</sup> is ethyl.
- 5 27. The compound of claim 23 wherein R<sup>2</sup> is alkyl.
28. The compound of claim 27 wherein R<sup>2</sup> is isobutyl.
29. The compound of claim 22 wherein R<sup>4</sup> is Cbz.
30. The compound of claim 29 wherein R<sup>2</sup> and R<sup>6</sup> are each isobutyl, and R<sup>1</sup> is selected from the group consisting of  
10 isobutyl, benzyl and ethyl.
31. The compound of claim 30 wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>6</sup> are each isobutyl.
32. A composition for inhibiting a serine protease or a cysteine protease comprising a compound of claim 1 or claim  
15 22.
33. A method for inhibiting serine proteases or cysteine proteases comprising contacting a protease selected from the group consisting of serine proteases and cysteine proteases with an inhibitory amount of a compound of claim 1 or claim  
20 22.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/14719

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 544/391; 546/146; 549/388; 560/159; 564/155, 169; 514/255, 514/307, 454, 490, 616, 621.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE STRUCTURE SEARCH

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P ----- Y, P	CHATTERJEE et al. Xanthene derived potent nonpeptidic inhibitors of recombinant Human Calpain I. Bioorganic & Medicinal Chemistry Letters. 09 July 1996, Vol. 6, No. 13, pages 1619-1622. See entire document, especially Table 1.	1-6, 9-10, 14, 17, 18, 32-33 ----- 7-8, 15-16
X, P ----- Y, P	US 5,498,616 A (MALLAMO ET AL.) 12 March 1996. See intermediates in examples 35-36.	1-3, 10, 32 ----- 6-8
X, P	SEBASTIAN et al. Effect of enzyme-substrate interactions away from the reaction site on carboxy peptidase A catalysis. Bioorganic Chemistry. September 1996, Vol. 24, No. 3, pages 290-303. See page 292 preparation of compound 1 and Tables 1 and 2.	1, 3, 32-33

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

03 DECEMBER 1996

Date of mailing of the international search report

15 JAN 1997

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

EMILY BERNHARDT

Telephone No. (703) 308-1235

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/14719

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, P	US 5,498,728 A (SOHDA ET AL.) 12 March 1996. See Table 14, example number 189.	1, 3, 4, 32-33
A, P	US 5,545,640 A (BEAULIEU ET AL.) 13 August 1996. See entire document.	1-33

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/14719

## A. CLASSIFICATION OF SUBJECT MATTER: IPC (6):

C07D 295/185, 217/06, 311/90; C07C 271/20, 237/22, 235/74; A61K 31/495, 31/47, 31/35, 31/22, 31/16.

## A. CLASSIFICATION OF SUBJECT MATTER: US CL :

544/391; 546/146; 549/388; 560/159; 564/155, 169; 514/255, 514/307, 454, 490, 616, 621.

## BOX I. OBSERVATIONS WHERE CLAIMS WERE FOUND UNSEARCHABLE

2. Where no meaningful search could be carried out, specifically:

The structural makeup (much less its point of attachment to the succinoyl side chain) of "Q" as carbohydrates, heteroaryl, heteroalkyl, arylheteroalkyl is not set forth in the claims or in the description pages such that the generic permutations embraced by these Q variables can be readily classified and thus no meaningful search can be made as to these embodiments. Remaining Q variables in the claims based on the classification of various examples has been searched.

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

Group I, claims 1-9, 14-17, and 32-33 drawn to compounds, compositions and use where Q=aryl of 6-14 carbons or aralkyl of 7-15 carbons.

Group II, claims 1-5, 8, 11-12, 19-20, 22-31, and 32-33 drawn to compounds, compositions and use where Q=alkyl optionally substituted with J, alkoxy, aralkoxy, CH(C<sub>4</sub>H<sub>9</sub>) NHCbz, CH<sub>2</sub>N(C<sub>4</sub>H<sub>9</sub>)Cbz.

Group III, claims 1-5, 10, 13, 18, 21, and 32-33 drawn to compounds, compositions and use where Q=xanthene-9-yl, rings of formula II and III.

Groups I-III are not so linked as to form a single, general inventive concept as required by PCT Rule 13.1. The groups relate to compounds of considerable structural dissimilarity which as a result are separately classified and are made and used independently of each other and are not recognized equivalents of each other.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/14719

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.: 1-5, 32-33 (in-part)  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
  
Please See Extra Sheet.
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.